Human medicines European public assessment report (EPAR): Palsonify, paltusotine, Status: Opinion
Human medicines European public assessment report (EPAR): Poherdy, pertuzumab, Status: Opinion
Human medicines European public assessment report (EPAR): Tuyory, tocilizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Status: Opinion
Human medicines European public assessment report (EPAR): Zandoriah, teriparatide, Status: Opinion
Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 February 2026
Summary of opinion: Jorveza, 26/02/2026 Positive
Summary of opinion: Olumiant, 26/02/2026 Positive
Human medicines European public assessment report (EPAR): Rhapsido, remibrutinib, Status: Opinion